# A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)

> **NCT04958265** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **Hoffmann-La Roche** · enrollment: 41 (actual)

## Conditions studied

- Atypical Hemolytic Uremic Syndrome

## Interventions

- **DRUG:** Crovalimab

## Key facts

- **NCT ID:** NCT04958265
- **Lead sponsor:** Hoffmann-La Roche
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2021-11-17
- **Primary completion:** 2025-07-04
- **Final completion:** 2029-05-19
- **Target enrollment:** 41 (ACTUAL)
- **Last updated:** 2026-03-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04958265

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04958265, "A Study Evaluating the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of Crovalimab in Pediatric Participants With Atypical Hemolytic Uremic Syndrome (aHUS)". Retrieved via AI Analytics 2026-07-15 from https://api.ai-analytics.org/clinical/NCT04958265. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*